Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.70 |
| ▸ | MMP1 | P03956 | 7/20 | 0.70 |
| ▸ | MMP3 | P08254 | 6/20 | 0.70 |
| ▸ | MMP2 | P08253 | 5/20 | 0.70 |
| ▸ | MMP13 | P45452 | 4/20 | 0.70 |
| ▸ | MMP7 | P09237 | 1/20 | 0.70 |
| ▸ | MMP14 | P50281 | 1/20 | 0.70 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6547584 | 1.00 | MMP9 (0.70) | MMP9MMP1MMP3MMP2MMP13 | |
| SCHEMBL7254495 | 0.88 | MMP9 (0.84) | MMP9MMP1MMP3MMP2MMP13 | |
| SCHEMBL6554608 | 0.88 | MMP9 (0.84) | MMP9MMP1MMP3MMP2MMP13 | |
| SCHEMBL12300383 | 0.83 | MMP1 (0.83) | MMP9MMP1MMP3MMP2MMP13 | |
| Rebimastat SCHEMBL12946005 | 0.82 | MMP1 (1.00) | MMP9MMP1MMP3MMP2MMP13 | |
| Rebimastat SCHEMBL645121 | 0.82 | MMP1 (1.00) | MMP9MMP1MMP3MMP2MMP13 | |
| SCHEMBL13282886 | 0.82 | MMP9 (0.73) | MMP9MMP1MMP3MMP2MMP13 | |
| Rebimastat SCHEMBL12247619 | 0.82 | MMP1 (1.00) | MMP9MMP1MMP3MMP2MMP13 | |
| Rebimastat SCHEMBL4826862 | 0.82 | MMP1 (1.00) | MMP9MMP1MMP3MMP2MMP13 | |
| Rebimastat SCHEMBL2379355 | 0.82 | MMP1 (1.00) | MMP9MMP1MMP3MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818622-B2 | ADMINISTERING OVER A PERIOD OF AT LEAST THREE MONTHS A MATRIX METALLOPROTEINASE INHIBITOR FOR TREATMENT OF A PATIENT HAVING CANCER OR INFLAMMATION | DARWIN DISCOVERY LTD. (GB) | 2004-11-16 | — | — | US | claimed |
| EP-0981366-B1 | SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS | DARWIN DISCOVERY LTD (GB) | 2004-01-21 | — | — | EP | claimed |
| US-20020173530-A1 | Single morphic forms of metalloproteinase inhibitors | KATZ RUTH BERNICE (GB) | 2002-11-21 | — | — | US | claimed |
| US-20020035065-A1 | Selective MMP inhibitors having reduced side-effects | BIRD JOHN (GB) | 2002-03-21 | — | — | US | claimed |
| US-20020025980-A1 | Single morphic forms of metalloproteinase inhibitors | KATZ RUTH BERNICE (GB) | 2002-02-28 | — | — | US | claimed |
| US-6277827-B1 | Single morphic forms of metalloproteinase inhibitors | DARWIN DISCOVERY, LTD. (GB) | 2001-08-21 | — | — | US | claimed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| EP-1957112-A2 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | Sanna, Pietro Paolo (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062048-A2 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SCRIPPS RESEARCH INST (US) | 2007-05-31 | — | — | WO | disclosed |
| US-6818622-B2 | ADMINISTERING OVER A PERIOD OF AT LEAST THREE MONTHS A MATRIX METALLOPROTEINASE INHIBITOR FOR TREATMENT OF A PATIENT HAVING CANCER OR INFLAMMATION | DARWIN DISCOVERY LTD. (GB) | 2004-11-16 | — | — | US | disclosed |
| EP-0981366-B1 | SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS | DARWIN DISCOVERY LTD (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-20020173530-A1 | Single morphic forms of metalloproteinase inhibitors | KATZ RUTH BERNICE (GB) | 2002-11-21 | — | — | US | disclosed |
| US-20020173530-A1 | Single morphic forms of metalloproteinase inhibitors | KATZ RUTH BERNICE (GB) | 2002-11-21 | — | — | US | disclosed |
| US-20020035065-A1 | Selective MMP inhibitors having reduced side-effects | BIRD JOHN (GB) | 2002-03-21 | — | — | US | disclosed |
| US-20020025980-A1 | Single morphic forms of metalloproteinase inhibitors | KATZ RUTH BERNICE (GB) | 2002-02-28 | — | — | US | disclosed |
| US-20020025980-A1 | Single morphic forms of metalloproteinase inhibitors | KATZ RUTH BERNICE (GB) | 2002-02-28 | — | — | US | disclosed |
| US-6277827-B1 | Single morphic forms of metalloproteinase inhibitors | DARWIN DISCOVERY, LTD. (GB) | 2001-08-21 | — | — | US | disclosed |
| US-6277827-B1 | Single morphic forms of metalloproteinase inhibitors | DARWIN DISCOVERY, LTD. (GB) | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | MMP9 631/4885MMP1 1050/4885MMP3 233/4885 |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | MMP9 631/4885MMP1 1050/4885MMP3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.